PEDIATRICS Vol. 88 No. 2 August 1991, pp. 265-268
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Goren, A.
Right arrow Articles by Goldstein, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goren, A.
Right arrow Articles by Goldstein, R.

Fish Oil Treatment of Hyperlipidemia in Children and Adolescents Receiving Renal Replacement Therapy

Avner Goren MD1, Alfred Drukker MD, PhD1, Halina Stankiewicz MSc2, and Robert Goldstein PhD2

1 From the Division of Pediatric Nephrology, Shaare Zedek Medical Center, Jerusalem, Israel
2 From the Gastroenterology Research Laboratory, Shaare Zedek Medical Center, Jerusalem, Israel

The effect of 8 weeks of daily oral fish oil supplementation in a dose of 3 to 8 g/d on serum lipid levels was studied in 16 patients, 7 to 8 years of age, who had end-stage renal disease and were receiving renal replacement therapy. Fasting serum cholesterol (CHOL), triglyceride (TG) levels, and lipoprotein profiles were measured before therapy, 8 weeks after fish oil supplementation, and 4 weeks after its cessation. During 8 weeks of treatment the mean serum CHOL level did not change. The mean serum TG level, however, decreased significantly (P < .01) from 236 ± 31 mg/dL to 171 ± 21 mg/dL (27.5%). Four weeks after treatment was stopped, the mean serum TG level returned to a value not significantly different from the pretreatment level (208 ± 30 mg/dL). In a subgroup of 11 excessively hyperlipidemic patients, with serum CHOL and TG levels ge50% of the 90th percentile for age and sex, the mean serum TG level decreased even more (30.8%), from 286 ± 35 mg/dL to 198 ± 24 mg/dL (P < .01), and the mean CHOL/high-density lipoprotein CHOL ratio decreased from 8.4 ± 1.2 to 7.4 ± 1.3 (P < .05). Blood pressure and platelet counts remained stable during the entire study period. Side effects of the treatment were minimal. These results show that dietary fish oil supplementation reduces serum TG levels in young patients receiving renal replacement therapy and improves their "atherogenic" serum lipoprotein profile.

Key Words: fish oil • chronic renal failure • renal replacement therapy • cholesterol • lipids • triglycerides • lipoproteins • hyperlipidemia

Submitted on July 25, 1990
Accepted on October 4, 1990




This article has been cited by other articles:


Home page
 CJASNHome page
A. Friedman and S. Moe
Review of the Effects of Omega-3 Supplementation in Dialysis Patients
Clin. J. Am. Soc. Nephrol., March 1, 2006; 1(2): 182 - 192.
[Abstract] [Full Text] [PDF]